HCV

Hepatitis C virus



Hepatitis C virus (HCV) is a positive-strand RNA virus grouped in the genus Hepacivirus within the family Flaviviridae. HCV is classified into at least 6 genotypes (gt), and its error-prone polymerase leads to more than 50 subtypes. The long open reading frame, which encodes the HCV polyprotein, is processed by host and viral proteases and gives rise to three structural proteins (the capsid protein core and envelope glycoproteins E1 and E2) and seven nonstructural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B). NS2 and p7 are essential for virus assembly but not RNA replication, whereas NS3 to NS5B are involved in a membrane-associated RNA replicase complex (RC). The NS3 protein is composed of a serine protease and an RNA helicase/nucleoside triphosphatase (NTPase), NS4A serves as a cofactor for NS3 serine protease, NS5B is the RNA-dependent RNA polymerase, and NS5A is considered to play key roles in multiple steps of the HCV life cycle.NS5A inhibitors exhibit a rapid inhibition of virus infectivity shortly after administration to HCV-infected cells.

The HCV protein NS5A prevents the apoptosis-enabling loss of intracellular potassium by inhibiting Kv2.1 function and thus blocking hepatocyte cell death.

The HCV RNA-dependent RNA polymerase (RdRp) has long been a prime target for antiviral development because of its critical role in viral replication and the absence of a mammalian homologous enzyme.

The combination of lucidone and alpha interferon, the protease inhibitor Telaprevir, the NS5A inhibitor BMS-790052, or the NS5B polymerase inhibitor PSI-7977, synergistically suppresses HCV RNA replication.

HCV Inhibitors & Modulators

4-Phenoxybenzylamine

Cat. No.: HY-18563

Bioactivity: 4-Phenoxybenzylamine inhibits the function of the **NS3** protein by stabilizing an inactive conformation with an **IC_{50}** of about 500 μM against FL NS3/4a.

Purity: 96.69%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg



ABT-072

Cat. No.: HY-101634

Bioactivity: ABT-072 is a nonnucleoside **NS5B polymerase** inhibitor and a candidate drug evaluated for treatment of hepatitis C virus.

Purity: 99.0%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 20 mg



ACH-806

(GS9132)

Cat. No.: HY-19512

Bioactivity: ACH-806 is an **NS4A** antagonist which can inhibit Hepatitis C Virus (**HCV**) replication with an **EC_{50}** of 14 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



Alisporivir

(DEB-025; Debio-025; UNIL-025)

Cat. No.: HY-12559

Bioactivity: Alisporivir (DEB-025; Debio-025) is a **cyclophilin** inhibitor molecule with potent anti-hepatitis C virus (**HCV**) activity.

Purity: 98.67%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Anguizole

Cat. No.: HY-13321

Bioactivity: Anguizole is a small molecule inhibitor of HCV replication and alters NS4B's subcellular distribution.

Purity: 99.33%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Artemisinin

(Qinghaosu; NSC 369397)

Cat. No.: HY-B0094

Bioactivity: Artemisinin is an **anti-malarial** drug isolated from the aerial parts of Artemisia annua L. plants.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 200 mg, 500 mg



Asunaprevir

(BMS-650032)

Cat. No.: HY-14434

Bioactivity: Asunaprevir is a potent **hepatitis C virus (HCV) NS3 protease** inhibitor, with **IC_{50}** of 0.2 nM-3.5 nM.

Purity: 99.27%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg



Balapiravir

(Ro 4588161; R1626)

Cat. No.: HY-10443

Bioactivity: Balapiravir (R1626, Ro 4588161) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479).

Purity: 98.11%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Beclabuvir

(BMS-791325)

Cat. No.: HY-12429

Bioactivity: Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (**HCV**) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with **IC_{50}** of < 28 nM.

Purity: 99.81%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Boceprevir

(EBP 520; SCH 503034)

Cat. No.: HY-10237

Bioactivity: Boceprevir is a novel, potent, highly selective, orally bioavailable **HCV NS3 protease** inhibitor with **K_i** of 14 nM in both enzyme assay and **EC_{90}** of 350 nM in cell-based replicon assay.

Purity: 99.12%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Celgosivir

(MBI 3253; MDL 28574; MX3253) Cat. No.: HY-16134

Bioactivity: Celgosivir (MBI 3253; MDL 28574; MX3253) is a novel α-glucosidase I inhibitor, an enzyme that plays a critical role in viral maturation by initiating the processing of the N-linked oligosaccharides of viral envelope glycoproteins.[1]

Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



Celgosivir hydrochloride (MBI 3253 (hydrochloride); MDL 28574 (hydrochloride); MX3253 (hydrochloride))

Cat. No.: HY-16134A

Bioactivity: Celgosivir hydrochloride (MDL 28574A) is an **α-glucosidase I** inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an **IC_{50}** of 1.27 μM in in vitro assay.

Purity: 98.0%
Clinical Data: Phase 2
Size: 10mM x 1mL in Water, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



Clemizole

Cat. No.: HY-30234

Bioactivity: Clemizole is an **H1 histamine receptor** antagonist, is found to substantially inhibit **HCV** replication. The **IC_{50}** of Clemizole for RNA binding by **NS4B** is 24±1 nM, whereas its **EC_{50}** for viral replication is 8 μM.

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg



Clemizole hydrochloride

Cat. No.: HY-30234A

Bioactivity: Clemizole hydrochloride is an **H1 histamine receptor** antagonist, is found to substantially inhibit **HCV** replication. The **IC_{50}** of Clemizole for RNA binding by **NS4B** is 24±1 nM, whereas its **EC_{50}** for viral replication is 8 μM.

Purity: 99.32%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Cyclophilin inhibitor 1

Cat. No.: HY-112712

Bioactivity: Cyclophilin inhibitor 1 is a potent and orally bioavailable **cyclophilin A** inhibitor, with a **K_d** of 5 nM, shows effective anti- **HCV** activity, with an **EC_{50}** of 98 nM for HCV 2a [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Daclatasvir

(BMS-790052; EBP 883) Cat. No.: HY-10466

Bioactivity: Daclatasvir is a potent **HCV NS5A** protein inhibitor, with mean **EC_{50}** values of 50 and 9 pM against genotype 1a and 1b replicons, respectively.

Purity: 99.31%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Daclatasvir dihydrochloride

(BMS-790052 dihydrochloride) Cat. No.: HY-10465

Bioactivity: Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. IC50 Value: 9-50 pM Target: HCV NS5A Daclatasvir has broad genotype coverage...

Purity: 99.70%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Danoprevir

(ITMN-191; R7227; RO5190591; RG7227) Cat. No.: HY-10238

Bioactivity: Danoprevir is a **NS3/4A protease** inhibitor for **hepatitis C virus (HCV)** with **IC_{50}** of 0.2-3.5 nM. The inhibition effect on HCV genotypes 1A/1B/4/5/6 is approximately 10-fold higher than 2B/3A.

Purity: 97.13%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg



Dasabuvir

(ABT-333) Cat. No.: HY-13998

Bioactivity: Dasabuvir (ABT-333) is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the **HCV NS5B** gene, inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates, with **IC_{50}** between 2.2 and 10.7 nM.

Purity: 98.05%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Elbasvir

(MK-8742) Cat. No.: HY-15789

Bioactivity: Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (**HCV NS5A**) inhibitor with **EC_{50}**s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Furaprofen

(R803) Cat. No.: HY-U00213

Bioactivity: Furaprofen (R803) is an effective **HCV replication** inhibitor. Furaprofen (R803) is substantially more potent against genotype **1a** and **1b** replicons (**EC_{50}**, ~30 nM) than against the genotype 2a replicon (EC $_{50}$, ~1,000 nM).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



Glecaprevir

(ABT-493) Cat. No.: HY-17634

Bioactivity: Glecaprevir is a novel **HCV NS3/4A protease** inhibitor, with **IC_{50}** values ranging from 3.5 to 11.3 nM.

Purity: 99.65%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg



Grazoprevir

(MK-5172) Cat. No.: HY-15298

Bioactivity: Grazoprevir (MK-5172) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with **K_i**s of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.

Purity: 99.21%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Grazoprevir hydrate

(MK-5172 (hydrate)) Cat. No.: HY-15298B

Bioactivity: Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with **K_i**s of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.

Purity: 99.58%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Grazoprevir potassium salt

(MK-5172 (potassium salt)) Cat. No.: HY-15298A

Bioactivity: Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with **K_i**s of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.

Purity: 99.35%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Grazoprevir sodium salt

(MK-5172 (sodium salt)) Cat. No.: HY-15298C

Bioactivity: Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with **K_i**s of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg



HCV-IN-3

Cat. No.: HY-18564

Bioactivity: HCV-IN-3 is a **hepatitis C virus (HCV) NS3/4a** protein inhibitor, with an **IC_{50}** of 20 μM, a **K_d** of 29 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Inarigivir soproxil

(SB9200) Cat. No.: HY-109035

Bioactivity: Inarigivir soproxil is an agonist of innate immunity and shows potent antiviral activity against resistant hepatitis C virus **(HCV)** variants, with **EC_{50}s** of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems.

Purity: 98.16%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



JTK-853

Cat. No.: HY-19921

Bioactivity: JTK-853 is a novel, non-nucleoside **Hepatitis C Virus** (**HCV**) **polymerase** inhibitor which shows effective antiviral activity in **HCV replicon** cells with **EC_{50}**s of 0.38 and 0.035 μM in genotype 1a H77 and 1b Con1 strains, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg



KIN1408

Cat. No.: HY-19961

Bioactivity: KIN1408 is an antiviral small molecule compound, as agonists of the RLR pathway. Target: KIN1408 activate IRF3 through MAVS, thereby inhibiting infection by viruses of the families Flaviviridae (West Nile virus, dengue virus and hepatitis C virus), Filoviridae (Ebola virus), Orthomyxoviridae (influenza...

Purity: 99.55%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Ledipasvir

(GS-5885) Cat. No.: HY-15602

Bioactivity: Ledipasvir is an inhibitor of the **hepatitis C virus NS5A**, with **EC_{50}**s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively.

Purity: 99.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Ledipasvir acetone

(GS-5885 acetone) Cat. No.: HY-15602A

Bioactivity: Ledipasvir acetone is the active pharmaceutical ingredient of Ledipasvir. Ledipasvir is an inhibitor of the **hepatitis C virus NS5A**, with **EC_{50}** values of 34 pM against GT1a and 4 pM against GT1b replicon.

Purity: 99.95%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Ledipasvir D-tartrate

(GS-5885 D-tartrate) Cat. No.: HY-15602B

Bioactivity: Ledipasvir D-tartrate is an inhibitor of the **hepatitis C virus NS5A**, with **EC_{50}** values of 34 pM against GT1a and 4 pM against GT1b replicon.

Purity: 99.73%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Ledipasvir diacetone

(GS-5885 diacetone) Cat. No.: HY-15602D

Bioactivity: Ledipasvir diacetone is the active pharmaceutical ingredient of Ledipasvir. Ledipasvir is an inhibitor of the **hepatitis C virus NS5A**, with **EC_{50}** values of 34 pM against GT1a and 4 pM against GT1b replicon.

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg



Mecarbinate

(Dimecarbin; Dimecarbine; Dimekarbin) Cat. No.: HY-B0376

Bioactivity: Mecarbinate is an anti-hepatitis C virus (HCV) agent.

Purity: 98.34%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Mericitabine

(RG 7128; R-7128; PSI 6130 diisobutyrate) Cat. No.: HY-10240

Bioactivity: Mericitabine (R-7128) is a nucleoside inhibitor of the **HCV NS5B polymerase** that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication.

Purity: 99.34%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Merimepodib

(VI-21497; VX-497; MMP) Cat. No.: HY-13986

Bioactivity: Merimepodib is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (**IMPDH**) with broad spectrum antiviral activities.

Purity: 98.22%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Narlaprevir

(SCH 900518) Cat. No.: HY-10300

Bioactivity: Narlaprevir is a potent, selective, orally bioavailable NS3 protease inhibitor(Ki=6 nM; EC90=40 nM)

Purity: 97.51%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Nesbuvir

(HCV-796) Cat. No.: HY-14775

Bioactivity: Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (**HCV**) nonstructural protein 5B (**NS5B**) polymerase.

Purity: 98.11%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



NIM811

((Melle-4)cyclosporin; SDZ NIM811) Cat. No.: HY-P0025

Bioactivity: NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is a potent and bioavailable **mitochondrial permeability transition** and **cyclophilin** dual inhibitor, which exhibits potent in vitro activity against hepatitis C virus (HCV) [1] [2].

Purity: 99.55%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



NM107

(2'-C-Methylcytidine; NM-107) Cat. No.: HY-10468

Bioactivity: NM107 is a inhibitors of HCV RNA replication with IC50 of 7.0 μM in vitro.

Purity: 99.52%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg



Nucleoside-Analog-1

Cat. No.: HY-77651

Bioactivity: Nucleoside-Analog-1 is a 4'-Azidocytidine analogue against Hepatitis C virus replication.

Purity: 95.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg



Nucleoside-Analog-2

Cat. No.: HY-77652

Bioactivity: Nucleoside-Analog-2 is a 4'-Azidocytidine analogue against Hepatitis C virus (**HCV**) replication.

Purity: 95.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg



Ombitasvir

(ABT-267) Cat. No.: HY-13997

Bioactivity: Ombitasvir is a potent inhibitor of the **hepatitis C virus protein NS5A**, with EC_{50}s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.

Purity: 99.79%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Paritaprevir

(ABT-450; Veruprevir) Cat. No.: HY-12594

Bioactivity: Paritaprevir (ABT-450) is a potent non-structural protein 3/4A (**NS3/4A**) protease inhibitor with EC_{50}s of 1 and 0.21 nM against **HCV** 1a and 1b, respectively.

Purity: 99.85%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Peretinoin

(NIK333) Cat. No.: HY-100008

Bioactivity: Peretinoin is an oral acyclic retinoid, inhibits HCV RNA amplification and virus release by altering lipid metabolism. Target: HCV in vitro: Peretinoin is an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma....

Purity: 98.38%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

PSI-352938

(PSI-938) Cat. No.: HY-15231

Bioactivity: PSI-352938 (PSI-938) is a hepatitis C virus (**HCV**) nucleotide inhibitor.

Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg, 20 mg



PSI-6130

(R 1656) Cat. No.: HY-10165

Bioactivity: PSI-6130 is a potent and selective inhibitor of **HCV NS5B polymerase**, and inhibits HCV replication with a mean IC_{50} of 0.6 μM.

Purity: 99.39%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg



PSI-6206

(RO 2433; GS-331007) Cat. No.: HY-15236

Bioactivity: PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits **HCV replicon** with EC_{90} of >100 μM.

Purity: 99.89%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



PSI-6206 13CD3 (RO-2433 13CD3; GS-331007 13CD3; Sofosbuvir metabolite GS-331007 13CD3)

Cat. No.: HY-15236S

Bioactivity: PSI-6206 13CD3 is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits **HCV replicon** with EC_{90} of >100 μM.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg



PSI-7409

Cat. No.: HY-15745

Bioactivity: PSI-7409 is the active 5'-triphosphate metabolite of Sofosbuvir (PSI-7977). Sofosbuvir (PSI-7977) is a selective and highly active nucleotide analog inhibitor of **HCV**.

Purity: 96.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



PSI-7409 tetrasodium

Cat. No.: HY-15745A

Bioactivity: PSI-7409 tetrasodium is an active 5'-triphosphate metabolite of sofosbuvir (PSI-7977), inhibiting **HCV NS5B polymerases**, with $\mathbf{IC_{50}}$s of 1.6, 2.8, 0.7 and 2.6 μM for GT 1b_Con1, GT 2a_JFH1, GT 3a, and GT 4a NS5B polymerases, respectively.

Purity: 96.49%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 1 mg, 5 mg, 10 mg, 25 mg



PSI-7976

Cat. No.: HY-15005A

Bioactivity: PSI-7976 is the isomer of PSI-7977. PSI-7977 is an active inhibitor of **HCV** RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (**HCV**) activity.

Purity: 98.24%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



R-1479

(4'-Azidocytidine)

Cat. No.: HY-10444

Bioactivity: R-1479 is a specific inhibitor of **HCV replication** in the HCV subgenomic replicon system ($\mathbf{IC_{50}}$=1.28 μM).

Purity: 99.44%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Ribavirin

(ICN-1229)

Cat. No.: HY-B0434

Bioactivity: Ribavirin (ICN-1229) is an **antiviral** agent against a broad spectrum of viruses including **HCV**, **HIVI**, and **RSV**.

Purity: 98.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water, 100 mg, 200 mg, 500 mg



RIG-1 modulator 1

Cat. No.: HY-107902

Bioactivity: RIG-1 modulator 1 is an anti-viral compound which can be useful for the treatment of viral infections including **influenza virus**, **HBV**, **HCV** and **HIV** extracted from patent WO 2015172099 A1.

Purity: 98.81%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg



RO-9187

Cat. No.: HY-10870

Bioactivity: RO-9187 is a potent inhibitor of **HCV** virus replication with an $\mathbf{IC_{50}}$ of 171 nM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg



Simeprevir

(TMC435)

Cat. No.: HY-10241

Bioactivity: Simeprevir is a potent **HCV NS3/4A protease** inhibitor which suppresses HCV replication with $\mathbf{EC_{50}}$ of 8 nM.

Purity: 99.34%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Sofosbuvir

(PSI-7977; GS 7977)

Cat. No.: HY-15005

Bioactivity: Sofosbuvir (PSI-7977) is an **HCV** RNA replication inhibitor with an $\mathbf{EC_{50}}$ of 92 nM.

Purity: 99.99%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g



Sofosbuvir 13CD3

(PSI-7977 13CD3; GS-7977 13CD3)

Cat. No.: HY-15005S

Bioactivity: Sofosbuvir 13CD3 is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of **HCV** RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (**HCV**) activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Sofosbuvir D6

(PSI-7977 D6; GS-7977 D6) Cat. No.: HY-15005S1

Bioactivity: Sofosbuvir D6 is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of **HCV** RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (**HCV**) activity.

Purity: 98.35%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg



Sofosbuvir impurity A

Cat. No.: HY-15005C

Bioactivity: Sofosbuvir impurity A, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg



Sofosbuvir impurity B

Cat. No.: HY-I0719

Bioactivity: Sofosbuvir impurity B is the less active impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of **HCV** RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (**HCV**) activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg



Sofosbuvir impurity C

Cat. No.: HY-15005B

Bioactivity: Sofosbuvir impurity C is the less active impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of **HCV** RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (**HCV**) activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg



Sofosbuvir impurity D

Cat. No.: HY-I0723

Bioactivity: Sofosbuvir impurity D is the less active impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of **HCV** RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (**HCV**) activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg



Sofosbuvir impurity E

Cat. No.: HY-I0727

Bioactivity: Sofosbuvir impurity E is the less active impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of **HCV** RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (**HCV**) activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg



Sofosbuvir impurity F

Cat. No.: HY-I0406

Bioactivity: Sofosbuvir impurity F, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg



Sofosbuvir impurity G

Cat. No.: HY-I0408

Bioactivity: Sofosbuvir impurity G, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg



Sofosbuvir impurity H

Cat. No.: HY-I0938

Bioactivity: Sofosbuvir impurity H, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg



Sofosbuvir impurity I

Cat. No.: HY-I0512

Bioactivity: Sofosbuvir impurity I, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg



Sofosbuvir impurity J

Cat. No.: HY-I0975

Bioactivity: Sofosbuvir impurity J, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



Sofosbuvir impurity K

Cat. No.: HY-I0515

Bioactivity: Sofosbuvir impurity K, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.

Purity: 98.97%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



Sofosbuvir impurity L

Cat. No.: HY-I1196

Bioactivity: Sofosbuvir impurity L, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



Sofosbuvir impurity M

Cat. No.: HY-I0735

Bioactivity: Sofosbuvir impurity M, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.

Purity: 99.04%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



Sofosbuvir impurity N

Cat. No.: HY-I0513

Bioactivity: Sofosbuvir impurity N, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of **HCV** RNA replication, demonstrates potent anti-hepatitis C virus activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



Tegobuvir

(GS 333126; GS-9190)

Cat. No.: HY-10544

Bioactivity: Tegobuvir is a specific, covalent inhibitor of the **HCV NS5B polymerase**.

Purity: 98.52%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Telaprevir

(VX-950)

Cat. No.: HY-10235

Bioactivity: Telaprevir is a highly selective, reversible, and potent peptidomimetic inhibitor of the **HCV NS3-4A protease**, the steady-state inhibitory constant ($\mathbf{K_i}$) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide.

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



TMC647055 Choline salt

Cat. No.: HY-15591A

Bioactivity: TMC647055 choline salt is a cell-permeating, selective HCV NS5B inhibitor, eliciting a mean IC50 of 34 nM, as assessed in the RdRp primer-dependent transcription assay.

Purity: 99.75%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Tris(4-aminophenyl)methane

(Leucopararosaniline)

Cat. No.: HY-D0306

Bioactivity: Tris(4-aminophenyl)methane is a triphenylmethane dye. Tris(4-aminophenyl)methane is a weak HCV helicase inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg



Vaniprevir

(MK-7009)

Cat. No.: HY-10243

Bioactivity: Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease. IC50 Value: Target: HCV NS3/4A Protease; HCV vaniprevir (MK-7009) is a macrocyclic hepatitis C virus NS3/4a protease inhibitor, is active against both the genotype 1 and genotype 2 NS3/4a...

Purity: 99.60%
Clinical Data: Launched
Size: 5 mg, 10 mg



VCH-916

Cat. No.: HY-13465

Bioactivity: VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.

Purity: 99.51%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Velpatasvir

(GS-5816)

Cat. No.: HY-12530

Bioactivity: Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons.

Purity: 99.95%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg



VX-222

(VCH-222)

Cat. No.: HY-75800

Bioactivity: VX-222 (VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. IC50 Value: 0.94 μM (HCV NS5B 1a); 1.2 μM (HCV NS5B 1b) Target: HCV VX-222 is a small molecule non-nucleoside...

Purity: 99.76%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg